SAMHD1 and neoplasm: Furthermore, RNRi has potent monotherapy anticancer activity that would not be expected from direct SAMHD1 inhibitors, which is an important consideration when designing optimal combination therapies to tackle heterogeneity within both patient and tumour populations [165].